NLRP3-IN-26, with the CAS number 2927413-30-5, is a small molecule inhibitor specifically designed to target the NLRP3 inflammasome, a critical component of the innate immune response. This compound is part of a broader class of inflammasome inhibitors that aim to modulate inflammatory pathways, making it of interest in the context of various inflammatory diseases and conditions associated with excessive activation of the NLRP3 inflammasome. Characteristically, NLRP3-IN-26 exhibits a specific binding affinity to the NLRP3 protein, thereby inhibiting its activation and subsequent downstream signaling. This inhibition can potentially lead to a reduction in the production of pro-inflammatory cytokines, such as IL-1β and IL-18. The compound's efficacy and safety profile are typically evaluated through in vitro and in vivo studies, which assess its pharmacokinetics, bioavailability, and therapeutic potential. As research progresses, NLRP3-IN-26 may contribute to the development of novel therapeutic strategies for treating diseases characterized by chronic inflammation.

NLRP3-IN-26

2927413-30-5: NLRP3-IN-26, with the CAS number 2927413-30-5, is a small molecule inhibitor specifically designed to target the NLRP3 inflammasome, a critical component of the innate immune response. This compound is part of a broader class of inflammasome inhibitors that aim to modulate inflammatory pathways, making it of interest in the context of various inflammatory diseases and conditions associated with excessive activation of the NLRP3 inflammasome. Characteristically, NLRP3-IN-26 exhibits a specific binding affinity to the NLRP3 protein, thereby inhibiting its activation and subsequent downstream signaling. This inhibition can potentially lead to a reduction in the production of pro-inflammatory cytokines, such as IL-1β and IL-18. The compound's efficacy and safety profile are typically evaluated through in vitro and in vivo studies, which assess its pharmacokinetics, bioavailability, and therapeutic potential. As research progresses, NLRP3-IN-26 may contribute to the development of novel therapeutic strategies for treating diseases characterized by chronic inflammation.

<p>NLRP3-IN-26 (compound 15Z), with an IC50 of 0.13 μM, functions as an inhibitor of NLRP3. It is applicable in studies involving the DSS-induced colitis model [1].</p>

CAS 2927413-30-5

NLRP3-IN-26

NLRP3-IN-26

Ref: TM-T87017